Efficacy and Safety Study With MYL-1401H and Neulasta
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Neoplasms|Chemotherapy-Induced Febrile Neutropenia
Interventions: BIOLOGICAL: MYL-1401H|BIOLOGICAL: Neulasta
Sponsor: Mylan Inc.
Collaborators: Mylan GmbH